MA55891A - Synthèses en phase liquide convergente d'oligonucléotides - Google Patents

Synthèses en phase liquide convergente d'oligonucléotides

Info

Publication number
MA55891A
MA55891A MA055891A MA55891A MA55891A MA 55891 A MA55891 A MA 55891A MA 055891 A MA055891 A MA 055891A MA 55891 A MA55891 A MA 55891A MA 55891 A MA55891 A MA 55891A
Authority
MA
Morocco
Prior art keywords
oligonucleotides
liquid phase
phase syntheses
convergent
convergent liquid
Prior art date
Application number
MA055891A
Other languages
English (en)
Inventor
Firoz Antia
Yannick Fillon
Robert S Gronke
Takuya Hamagaki
Taisuke Ichimaru
Hong Jiang
William F Kiesman
Hien Nguyen
Xianglin Shi
Daisuke Takahashi
Wuming Yan
Xuan Zhou
Original Assignee
Ajinomoto Kk
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk, Biogen Ma Inc filed Critical Ajinomoto Kk
Publication of MA55891A publication Critical patent/MA55891A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA055891A 2019-05-08 2020-05-08 Synthèses en phase liquide convergente d'oligonucléotides MA55891A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962845160P 2019-05-08 2019-05-08

Publications (1)

Publication Number Publication Date
MA55891A true MA55891A (fr) 2022-03-16

Family

ID=70919104

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055891A MA55891A (fr) 2019-05-08 2020-05-08 Synthèses en phase liquide convergente d'oligonucléotides

Country Status (13)

Country Link
US (1) US12378276B2 (fr)
EP (1) EP3966219A2 (fr)
JP (2) JP7824080B2 (fr)
KR (1) KR20220007104A (fr)
CN (3) CN119143828A (fr)
AU (1) AU2020268415B2 (fr)
BR (1) BR112021022219A2 (fr)
CA (1) CA3139545A1 (fr)
EA (1) EA202193010A1 (fr)
IL (2) IL287798B2 (fr)
MA (1) MA55891A (fr)
MX (1) MX2021013587A (fr)
WO (1) WO2020227618A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013148283A1 (fr) 2012-03-30 2013-10-03 Isis Pharmaceuticals, Inc. Compositions et procédés pour moduler l'expression de tau pour réduire les crises d'épilepsie et modifier un syndrome neurodégénératif
TWI657819B (zh) 2013-07-19 2019-05-01 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
WO2022103842A1 (fr) 2020-11-11 2022-05-19 Biogen Ma Inc. Oligonucléotides, réactifs et préparation associée
PE20240648A1 (es) * 2021-07-23 2024-04-04 Biogen Ma Inc Metodos para reducir la expresion de tau
WO2024083746A1 (fr) 2022-10-17 2024-04-25 Bachem Holding Ag Procédé et composition pour la synthèse d'oligonucléotides
WO2024089953A1 (fr) * 2022-10-27 2024-05-02 住友化学株式会社 Procédé de production d'oligonucléotide
JPWO2024185775A1 (fr) 2023-03-06 2024-09-12
GB202305283D0 (en) * 2023-04-11 2023-05-24 Exactmer Ltd Liquid-phase process for preparing oligonucleotides
JP7433684B1 (ja) * 2023-05-24 2024-02-20 塩野フィネス株式会社 疑似固相保護基、それを用いたヌクレオシド保護体又はオリゴヌクレオチド保護体、オリゴアミダイト前駆体の製造方法
WO2025082632A1 (fr) 2023-10-16 2025-04-24 Bachem Holding Ag Procédé et composition pour la synthèse d'oligonucléotides
US20250206769A1 (en) * 2023-12-22 2025-06-26 Imec Vzw Synthesizing a Nucleic Acid or Nucleic Acid Analogue
WO2025235761A1 (fr) 2024-05-09 2025-11-13 Biogen Ma Inc. Réactifs et procédés de préparation d'oligonucléotides
WO2026085433A2 (fr) 2024-10-17 2026-04-23 Biogen Ma Inc. Procédés pour préparer des conjugués oligonucléotidiques

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT64554A (en) 1990-11-20 1994-01-28 Sankyo Co A process for preparing nucleinic acide derivatives of anesthetic effect and pharmaceutical compositions containing them as active ingredient
US5510476A (en) 1994-07-07 1996-04-23 Isis Pharmaceuticals, Inc. Carbocation scavenging during oligonucleotide synthesis
AU738032B2 (en) 1995-10-19 2001-09-06 Proligo Llc Method for solution phase synthesis of oligonucleotides
EP1386925A1 (fr) * 2002-07-31 2004-02-04 Girindus AG Procédé de préparation des oligonucleotides
ES2397113T3 (es) 2005-06-23 2013-03-04 Isis Pharmaceuticals, Inc. Composiciones y procedimientos para modular el corte y empalme de SMN2
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
JP5548852B2 (ja) 2009-05-29 2014-07-16 国立大学法人東京農工大学 疎水性基結合ヌクレオシド、疎水性基結合ヌクレオシド溶液、及び疎水性基結合オリゴヌクレオチド合成方法
CN115227709A (zh) 2009-06-17 2022-10-25 冷泉港实验室 用于在对象中调节smn2剪接的组合物和方法
US20120184724A1 (en) * 2009-09-22 2012-07-19 Agilent Technologies, Inc. Protected monomers and methods of deprotection for rna synthesis
JP5705512B2 (ja) 2010-11-26 2015-04-22 農工大ティー・エル・オー株式会社 高分散性液相支持体を用いたオリゴヌクレオチド合成法
US9029528B2 (en) * 2011-05-17 2015-05-12 Ajinomoto Co., Inc. Solution-based method of making oligonucleotides via phosphoramidite coupling
US8846885B2 (en) 2012-02-17 2014-09-30 Ajinomoto Co., Inc. Oligonucleotide with protected base
EP3296306B1 (fr) * 2012-02-17 2022-11-09 Ajinomoto Co., Inc. Oligonucléotide à bases protégées
IN2014DN10144A (fr) 2012-05-30 2015-08-21 Hokkaido System Science Co Ltd
WO2014077292A1 (fr) * 2012-11-14 2014-05-22 武田薬品工業株式会社 Procédé de synthèse en phase liquide d'un acide nucléique
MY192634A (en) 2014-04-01 2022-08-29 Biogen Ma Inc Compositions for modulating sod-1 expression
JP6733554B2 (ja) 2015-01-21 2020-08-05 味の素株式会社 沈殿促進剤およびそれを用いる沈殿化方法
WO2017104836A1 (fr) 2015-12-16 2017-06-22 味の素株式会社 Procédé de production d'oligonucléotides et nucléoside, nucléotide ou oligonucléotide
WO2017111137A1 (fr) * 2015-12-22 2017-06-29 味の素株式会社 Procédé de production d'oligonucléotides
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
TW201906855A (zh) 2017-05-02 2019-02-16 日商日產化學工業股份有限公司 寡核苷酸之製造方法

Also Published As

Publication number Publication date
EP3966219A2 (fr) 2022-03-16
AU2020268415A1 (en) 2021-12-23
CN119462804A (zh) 2025-02-18
IL287798B2 (en) 2025-09-01
JP2025138846A (ja) 2025-09-25
BR112021022219A2 (pt) 2022-03-22
WO2020227618A8 (fr) 2020-12-24
CN114206897A (zh) 2022-03-18
CN119143828A (zh) 2024-12-17
IL287798A (en) 2022-01-01
JP2022531876A (ja) 2022-07-12
AU2020268415B2 (en) 2026-04-23
AU2020268415A8 (en) 2022-01-20
US20220348602A1 (en) 2022-11-03
EA202193010A1 (ru) 2022-03-18
CA3139545A1 (fr) 2020-11-12
WO2020227618A2 (fr) 2020-11-12
US12378276B2 (en) 2025-08-05
WO2020227618A3 (fr) 2021-01-14
MX2021013587A (es) 2022-02-11
IL287798B1 (en) 2025-05-01
JP7824080B2 (ja) 2026-03-04
IL319933A (en) 2025-05-01
CN114206897B (zh) 2024-09-20
KR20220007104A (ko) 2022-01-18

Similar Documents

Publication Publication Date Title
IL287798A (en) Convergent syntheses of liquid-phase oligonucleotides
MA51066A (fr) Inhibiteurs d'intégrine
IL286487A (en) Technologies useful for oligonucleotide preparation
EP3953668A4 (fr) Procédé d'étalonnage pour débitmètre de liquide
EP3369108A4 (fr) Dispositif d'optimisation/collimateur de flux pouvant être polarisé pour chambre de pulvérisateur pvd
EP3484908A4 (fr) Supports solides non nucléosides et blocs de construction de phosphoramidite pour synthèse d'oligonucléotides
EP3583088A4 (fr) Synthèse de phéromones et de matériaux apparentés par métathèse d'oléfines
EP3360534A4 (fr) Produit cosmétique d'écran solaire pouvant être pulvérisé
IL284441A (en) One pot synthesis of sets of oligonucleotides
EP3871998A4 (fr) Réservoir d'azote liquide
EP3613511A4 (fr) Pulvérisateur de liquide de type à gâchette
FR3046038B1 (fr) Module de support de sac a dos pour une structure modulaire d'exosquelette
EP3438121A4 (fr) Procédé de synthèse en phase liquide d'oxytocine à l'aide de polypeptides
EP3590188A4 (fr) Respect de temps d'établissement/de maintien pour un signal répétitif concernant une horloge
EP3834809A4 (fr) Produit cosmétique à base d'huile
EP4073032A4 (fr) Synthèse chimique en flux d'isocyanates
EP4059711A4 (fr) Revêtement liquide
MA51795A (fr) Oligonucléotides pour moduler l'expression de tmem106b
EP3620035A4 (fr) Procédés et systèmes pour former un revêtement liquide d'une cavité
FR3074700B1 (fr) Systeme pour la distribution d'une phase liquide et/ou gazeuse dans une enceinte reactionnelle
EP3888726A4 (fr) Pompe de distribution de liquide
EP3650455A4 (fr) Procédé de synthèse d'acide nucléique en phase solide et composition liquide pour la synthèse d'acide nucléique en phase solide
MA52148A (fr) Peptides chimères pour administration d'antisens
EP4021996A4 (fr) Compositions d'encre électrophotographique liquide
MA49278A (fr) Oligonucléotides antisens pour moduler l'expression de htra1